Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mercredi, octobre 21
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Arrowhead Pharmaceuticals Inc
ARWR
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$59.85
0.93
1.58%
Dern. MÀJ: Oct 21, 1:15 PM
$59.50
0.58
0.98%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Arrowhead Pharma Financials
Arrowhead Pharma (ARWR) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Arrowhead Pharma Q3 EPS $(1.36) Misses $(1.32) Estimate, Sales $75.253M Beat $54.294M Estimate
Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.36) per share which missed the analyst consensus estimate of $(1.32) by 3.03 percent. This is a 7.94 percent decrease over losses of $(1.26) per share from
Benzinga Newsdesk
PRO
Arrowhead Pharma Q2 EPS $(0.93) Beats $(1.14) Estimate, Sales $73.737M Miss $79.991M Estimate
Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(0.93) per share which beat the analyst consensus estimate of $(1.14) by 18.42 percent. This is a 133.82 percent decrease over earnings of $2.75 per share from
Benzinga Newsdesk
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens
CRISPR Therapeutics highlights progress in clinical trials & uptake of Casgevy gene therapy. Pipeline also advancing with promising data.
Vandana Singh
Arrowhead Pharma Q1 Earnings Summary & Key Takeaways
Benzinga Insights
PRO
Arrowhead Pharma Q1 EPS $0.22 Beats $0.14 Estimate, Sales $264.033M Miss $270.066M Estimate
Arrowhead Pharma (NASDAQ:ARWR) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.14 by 59.42 percent. This is a 115.83 percent increase over losses of $(1.39) per share from
Benzinga Newsdesk
Earnings Scheduled For February 5, 2026
Benzinga Insights
